Intertoe squamous cell carcinoma developed in a patient with rheumatoid arthritis under etanercept therapy

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The use of tumor necrosis factor-α; (TNF-α;) inhibitors in the treatment of various inflammatory conditions has altered the field of medical therapeutics. Squamous cell carcinoma is the second most common cancer of the skin, usually affecting sun-exposed areas of the body. We present here the case of a 75-year-old woman with rheumatoid arthritis, who developed an intertoe squamous cell carcinoma (SCC) of the right foot. According to her history, she received etanercept and methotrexate for 5 years for rheumatoid arthritis. The rare localization of this cancer could suggest a possible linkage of the malignancy to the chronic intake of anti-TNF-α; treatment. This is the first reported case of an interdigital SCC developed under the use of an anti-TNF-α; agent.

Cite

CITATION STYLE

APA

Rallis, E., Bournia, V. K., Verros, C., & Iliopoulos, A. (2015). Intertoe squamous cell carcinoma developed in a patient with rheumatoid arthritis under etanercept therapy. Case Reports in Medicine, 2015. https://doi.org/10.1155/2015/315490

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free